AbbVie Inc. logo

AbbVie Inc. (ABBV)

Market Closed
27 Feb, 20:00
NYSE NYSE
$
232. 03
+7.34
+3.27%
$
397.32B Market Cap
42.2 P/E Ratio
1.63% Div Yield
4,213,578 Volume
10.28 Eps
$ 224.69
Previous Close
Day Range
225.1 232.19
Year Range
164.39 244.81
Want to track ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ABBV earnings report is expected in 54 days (23 Apr 2026)
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.

Zacks | 1 year ago
AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?

AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?

Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.

Zacks | 1 year ago
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?

AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?

AbbVie's lead drug, Humira, lost patent-protected market exclusivity in 2023, but sales have been relatively resilient to new competition. Despite losing billions in Humira revenue, total sales are still on the rise.

Fool | 1 year ago
10 Best Dividend Growth Stocks to Buy and Hold Forever

10 Best Dividend Growth Stocks to Buy and Hold Forever

These blue-chip companies have demonstrated strong dividend growth rates ranging from 7.69% to 15.8% annually over the past five years. The list includes diverse sectors such as retail, healthcare, technology, and finance, offering potential for portfolio diversification.

Fool | 1 year ago
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts

AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts

AbbVie (ABBV) closed at $172.32 in the latest trading session, marking a +0.69% move from the prior day.

Zacks | 1 year ago
AbbVie: Why I Sold My Shares At $175

AbbVie: Why I Sold My Shares At $175

We recently sold our ABBV shares at $175. The stock has reached our target valuation at this price. More fundamentally, we think the market has corrected its overreaction to the Humira patent cliff by now.

Seekingalpha | 1 year ago
Earnings Preview: AbbVie (ABBV) Q2 Earnings Expected to Decline

Earnings Preview: AbbVie (ABBV) Q2 Earnings Expected to Decline

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

AbbVie Inc. will announce its Q2 2024 earnings next Thursday, 25th July. The company has a new CEO, with insider Rob Michael taking the reins after long-term CEO Rick Gonzalez's retirement. Wall Street watches Humira's revenue post patent expiry in the US closely, and sold stock after Q1 showed a >30% YOY decline.

Seekingalpha | 1 year ago
7 High-Yield Dividend Stocks to Help Pay Your Bills

7 High-Yield Dividend Stocks to Help Pay Your Bills

While active acquisition is perhaps the most common methodology of gaining wealth, it's not always the most efficient. For example, even if you trade your hours for a generous paycheck, there are only so many hours available: in a day, in a week, in a month, you get the idea.

Investorplace | 1 year ago
3 Absurdly Cheap Stocks to Buy and Hold for Years

3 Absurdly Cheap Stocks to Buy and Hold for Years

Drugmaker AbbVie has been investing in its growth, and that strategy looks to be paying off. Verizon's stable business and low valuation make it practically a no-brainer buy for dividend investors.

Fool | 1 year ago
7 High-Yield Dividend Stocks Beating Inflation

7 High-Yield Dividend Stocks Beating Inflation

At this writing, current inflation rate is 3% over the past 12 months. That's the reading as of the end of June.

Investorplace | 1 year ago
7 Recession-Proof Stocks to Shield Your Portfolio in 2024

7 Recession-Proof Stocks to Shield Your Portfolio in 2024

U.S. News & World Report recently said the New York Fed's Recession Probability model hints that within the next 12 months, we stand a 55.8% chance of a recession. One can never be too safe though.

Investorplace | 1 year ago
Loading...
Load More